Work

Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study

Year: 2023

Type: article

Source: Journal of Drugs in Dermatology

DOI: 10.36849/jdd.7471

Authors: Jayme Heim, J. Gabriel Vasquez, Brad Schenkel, Neal Bhatia

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4385694635

FWCI: 0.444

Cites:

Cited by: 5

Related to: 10